Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Del Sol Research Management, LLC

Neither a doctor nor a teaching hospital

Research payments

$1,747,160

583 payments

Through program year 2025, Del Sol Research Management, LLC is reported as receiving $1,747,160 in research payments, across 583 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $564,530 19
2024 Research $829,471 19
2023 Research $146,395 22
2022 Research $102,452 353
2021 Research $62,879 154
2020 Research $5,753 3
2019 Research $35,680 13

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,137,547 13 payments
  2. Celgene Corporation $194,981 8 payments
  3. Novo Nordisk AS $161,731 505 payments
  4. Merck Sharp & Dohme Corporation $71,734 2 payments
  5. Teva Pharmaceuticals USA, Inc. $69,838 26 payments
  6. Genzyme Corporation $33,128 2 payments
  7. Bausch Health US, LLC $28,395 11 payments
  8. Exeltis, USA Inc. $24,143 10 payments
  9. AstraZeneca UK Limited $14,973 1 payment
  10. E.R. Squibb & Sons, L.L.C. $8,942 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele $733,713 2 payments
  2. a twelfeweek randomized doubleblind phase four study evaluating the effect of airsupra compared to albuterol administered as needed on changes in airway inflammation symptoms and rescue therapy utilization in adults with mild asthma darwin $169,134 5 payments
  3. A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler $132,623 3 payments
  4. Phase III CC-93538 Treat-Through (CC-93538-EE-001) Wk24 PE Primary - A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolesc $114,669 2 payments
  5. Nn9931-4553 $101,071 158 payments
  6. A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS $99,800 3 payments
  7. Nn9535-4352 $52,060 342 payments
  8. A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma $39,683 15 payments
  9. A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i $37,491 1 payment
  10. A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i $34,242 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record